Journal ArticleDOI
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Reads0
Chats0
TLDR
The SELECT-AXIS 2 non-radiographic axial spondyloarthritis study as mentioned in this paper was a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 113 sites across 23 countries (Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, France, Germany, Hungary, Russia, Slovakia, South Korea, Spain, Taiwan, Turkey, Ukraine, and the USA).About:
This article is published in The Lancet.The article was published on 2022-07-01. It has received 26 citations till now. The article focuses on the topics: Medicine & Placebo.read more
Citations
More filters
Journal ArticleDOI
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Q Hu,Qihui Bian,Dingchao Rong,Leiyun Wang,Jianan Song,Hsuan-Shun Huang,Jun Zeng,Jie Mei,Peng Wang +8 more
TL;DR: The role of the JAK/STAT pathway in mechanistic signaling, disease progression, immune environment, and therapeutic targets is discussed in this article . But, the authors do not discuss the mechanism of the pathway.
Journal ArticleDOI
Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?
TL;DR: In this paper , an overview of the treatment landscape of axial spondyloarthritis (axSpA) has been presented, including the use of biological disease-modifying drugs (bDMARDs) for axSpA.
Journal ArticleDOI
The Effect of Upadacitinib on Lipid Profile and Cardiovascular Events: A Meta-Analysis of Randomized Controlled Trials
Anastasios P Makris,Fotios Barkas,Petros P. Sfikakis,Evangelos Liberopoulos,Aris P. Agouridis +4 more
TL;DR: In this paper , the effect of upadacitinib, an oral JAK-1 selective inhibitor, on lipid profile and cardiovascular disease risk was systematically investigated in 15 randomized controlled trials.
Journal ArticleDOI
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Chen Xue,Qi Jason Yao,Xinyu Gu,Qingmiao Shi,Xin Yuan,Qingfei Chu,Zheng-fu Bao,Juan Lu,Lan-Ju Li +8 more
TL;DR: The Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway is an evolutionarily conserved mechanism of transmembrane signal transduction that enables cells to communicate with the exterior environment as discussed by the authors .
References
More filters
Journal ArticleDOI
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
Martin Rudwaleit,D. van der Heijde,Robert Landewé,Joachim Listing,Nurullah Akkoc,J Brandt,Jürgen Braun,C.T. Chou,Eduardo Collantes-Estevez,Maxime Dougados,Feng Huang,Jieruo Gu,Muhammad Asim Khan,Yesim Kirazli,Walter P. Maksymowych,Herman Mielants,Inge Juul Sørensen,Salih Ozgocmen,Euthalia Roussou,R. Valle-Oñate,Ulrich Weber,James Cheng-Chung Wei,Joachim Sieper +22 more
TL;DR: The new ASAS classification criteria for axial SpA can reliably classify patients for clinical studies and may help rheumatologists in clinical practice in diagnosing axial spondyloarthritis in those with chronic back pain.
Journal ArticleDOI
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
Joachim Sieper,M. Rudwaleit,Xenofon Baraliakos,J Brandt,Jürgen Braun,Ruben Burgos-Vargas,Maxime Dougados,K.-G. Hermann,Robert Landewé,Walter P. Maksymowych,D. van der Heijde +10 more
TL;DR: A comprehensive handbook on the most relevant aspects for the assessments of spondyloarthritis, covering classification criteria, MRI and x rays for sacroiliac joints and the spine, a complete set of all measurements relevant for clinical trials and international recommendations for the management of SpA are provided.
Journal ArticleDOI
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde,Sofia Ramiro,Robert Landewé,Xenofon Baraliakos,Filip Van den Bosch,Alexandre Sepriano,Alexandre Sepriano,Andrea Regel,Adrian Ciurea,Hanne Dagfinrud,Maxime Dougados,Maxime Dougados,Floris A. van Gaalen,Pál Géher,Irene E. van der Horst-Bruinsma,Robert D. Inman,Merryn Jongkees,Uta Kiltz,Tore K Kvien,Pedro Machado,Helena Marzo-Ortega,Anna Molto,Anna Molto,Victoria Navarro-Compán,Salih Ozgocmen,Fernando Pimentel-Santos,John D. Reveille,Martin Rudwaleit,Martin Rudwaleit,J. Sieper,Percival D. Sampaio-Barros,Dieter Wiek,Jürgen Braun +32 more
TL;DR: The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA and three overarching principles and 13 recommendations deal with surgery and spinal fractures.
Journal ArticleDOI
Ankylosing Spondylitis Disease Activity Score (ASDAS) : defining cut-off values for disease activity states and improvement scores
Pedro Machado,Robert Landewé,Elisabeth Lie,Tore K Kvien,Jürgen Braun,Daniel Baker,Désirée van der Heijde +6 more
TL;DR: Cut-off values for disease activity states and improvement using the Ankylosing SpondyloArthritis Disease Activity Score have been developed and proved to have external validity and a good performance compared to existing criteria.
Journal ArticleDOI
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis : results of a randomised placebo-controlled trial (ABILITY-1)
Joachim Sieper,Désirée van der Heijde,Maxime Dougados,Philip J. Mease,Walter P. Maksymowych,Matthew A. Brown,Vipin Arora,Aileen L. Pangan +7 more
TL;DR: Results from ABILITY-1 suggest that adalimumab has a positive benefit–risk profile in active nr-axSpA patients with inadequate response to NSAIDs and the safety profile was consistent with what is known for ad alimumab in ankylosing spondylitis and other diseases.